MT Newswires
CRISPR Says Zugo-cel Well-Tolerated in Phase 1 Autoimmune Rheumatic Diseases Trial
➖
AI Sentiment
Neutral
5/10
- Home
- CRSP
as of 12-23-2025 3:46pm EST
$56.70
$1.21
-2.10%
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Founded: | 2013 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 5.6B | IPO Year: | 2016 |
| Target Price: | $71.50 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.04 - $78.48 | Next Earning Date: | 02-10-2026 |
| Revenue: | $38,337,000 | Revenue Growth: | -81.10% |
| Revenue Growth (this year): | -58.24% | Revenue Growth (next year): | 723.84% |
AI-Powered CRSP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.38%
73.38%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
Prasad Raju
Sell
Chief Financial Officer
CRSP Dec 22, 2025
Avg Cost/Share
$56.11
Shares
10,000
Total Value
$559,548.75
Owned After
13,239
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Oct 17, 2025
Avg Cost/Share
$67.91
Shares
50,895
Total Value
$3,456,279.45
Owned After
254,201
SEC Form 4
Kulkarni Samarth
Sell
Chief Executive Officer
CRSP Oct 14, 2025
Avg Cost/Share
$66.60
Shares
4,242
Total Value
$282,517.20
Owned After
254,201
SEC Form 4
KASINGER JAMES R.
Sell
General Counsel and Secretary
CRSP Oct 14, 2025
Avg Cost/Share
$66.60
Shares
1,076
Total Value
$71,661.60
Owned After
83,402
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Prasad Raju | CRSP | Chief Financial Officer | Dec 22, 2025 | Sell | $56.11 | 10,000 | $559,548.75 | 13,239 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Oct 17, 2025 | Sell | $67.91 | 50,895 | $3,456,279.45 | 254,201 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Oct 14, 2025 | Sell | $66.60 | 4,242 | $282,517.20 | 254,201 | |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Oct 14, 2025 | Sell | $66.60 | 1,076 | $71,661.60 | 83,402 |
Latest CRISPR Therapeutics AG News
CRSP Breaking Stock News: Dive into CRSP Ticker-Specific Updates for Smart Investing
GlobeNewswire
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
CRISPR Therapeutics (CRSP): Revisiting Valuation After Recent Share Price Pullback
➖
AI Sentiment
Neutral
5/10
Compare CRSP vs Leading Stocks
See how CRSP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.